ISSN: 1300-7777 E-ISSN: 1308-5263
Autoantibodies against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia [Turk J Hematol]
Turk J Hematol. Ahead of Print: TJH-44442 | DOI: 10.4274/tjh.2016.0341  

Autoantibodies against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia

Ahmet Menteşe1, Nergiz Erkut2, Selim Demir3, Serap Özer Yaman4, Aysegül Sümer5, Seniz Doğramacı4, Ahmet Alver4, Mehmet Sönmez2
1Program of Medical Laboratory Techniques, Vocational School of Health Sciences, Karadeniz Technical University, 61080, Trabzon, Turkey
2Department of Hematology, Faculty of Medicine, Karadeniz Technical University, 61080, Trabzon, Turkey
3Department of Nutrition and Dietetics, Faculty of Health Sciences, Karadeniz Technical University, 61080, Trabzon, Turkey
4Department of Medical Biochemistry, Faculty of Medicine, Karadeniz Technical University, 61080, Trabzon, Turkey
5Department of Nursing, School of Health Services, Recep Tayyip Erdogan University, 53100, Rize, Turkey

Objective: Cancer, one of the principal causes of death, is a global social health problem. Autoantibodies developed against the organism’s self-antigens are detected in the sera of subjects with cancer. In recent years carbonic anhydrase (CA) I and II autoantibodies have been shown in some autoimmune diseases and carcinomas, but the mechanisms underlying this immune response have not yet been explained. The aim of this study was to evaluate CA I and II autoantibodies in patients with acute myeloid leukemia (AML) and to provide a novel perspective regarding the autoimmune basis of the disease.

Materials and Methods: Anti-CA I and II antibody levels were investigated using ELISA in serum samples from 30 patients with AML and 30 healthy peers.


Results: Anti-CA I and II antibody titers in the AML group were significantly higher compared with the control group (p=0.0001 and 0.018, respectively). A strong positive correlation was also determined between titers of anti-CA I and II antibodies (r=0.613, p=0.0001).
Conclusion: Our results suggest that these autoantibodies may be involved in the pathogenesis of AML. More extensive studies are now needed to reveal the entire mechanism.

Keywords: Acute myeloid leukemia, Autoantibody, Cancer, Carbonic anhydrase


Ahmet Menteşe1, Nergiz Erkut2, Selim Demir3, Serap Özer Yaman4, Aysegül Sümer5, Seniz Doğramacı4, Ahmet Alver4, Mehmet Sönmez2
1Program of Medical Laboratory Techniques, Vocational School of Health Sciences, Karadeniz Technical University, 61080, Trabzon, Turkey
2Department of Hematology, Faculty of Medicine, Karadeniz Technical University, 61080, Trabzon, Turkey
3Department of Nutrition and Dietetics, Faculty of Health Sciences, Karadeniz Technical University, 61080, Trabzon, Turkey
4Department of Medical Biochemistry, Faculty of Medicine, Karadeniz Technical University, 61080, Trabzon, Turkey
5Department of Nursing, School of Health Services, Recep Tayyip Erdogan University, 53100, Rize, Turkey

Amaç: Kanser, dünyadaki başlıca ölüm nedenlerinden birisi olup, küresel bir toplum sağlığı sorunudur. Organizmanın kendi antijenlerine karşı gelişen otoantikorlar pek çok kanser hastasının serumunda tespit edilmiştir. Son yıllarda karbonik anhidraz (CA) I ve II otoantikorlarının varlığı bazı otoimmün hastalıklarda ve kanser türlerinde gösterilmiştir, ancak bu immün yanıtın altında yatan mekanizmalar henüz açıklanabilmiş değildir. Bu çalışmanın amacı, akut miyeloid lösemili (AML) kişilerde, CA I ve II otoantikorlarının varlığını değerlendirmek ve hastalığın otoimmün temeline dair yeni bir bakış açısısağlamaktır.


Gereç ve Yöntem: 30 hasta ve 30 sağlıklı kontrolden elde edilen serum örneklerinde anti-CA I ve II antikor düzeyleri ELISA yöntemiyle belirlendi.

Bulgular: AML grubundaki anti-CA I ve II antikor düzeyleri kontrol grubu (p=sırasıyla 0.0001 ve 0.018 ) ile karşılaştırıldığında anlamlı derecede yüksek bulundu. Ayrıca CA I ve II otoantikor seviyeleri arasında güçlü bir pozitif korelasyon saptandı (r=0.613, p=0.0001).
Sonuç: Elde edilen sonuçlar bu otoantikorların AML patogenezinde rolü olabileceğini düşündürmektedir. Kesin mekanizmayı ortaya çıkarabilmek için daha kapsamlı çalışmalar gereklidir

Anahtar Kelimeler: Akut miyeloid lösemi, Kanser, Karbonik anhidraz, Otoantikor




Corresponding Author: Ahmet Menteşe, Türkiye


TOOLS
Uncorrected Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686